SAR445088 Shows Sustained Complement Inhibition in CAD
Sutimlimab for the Treatment of Cold Agglutinin Disease
12 Mistakes You Make at the Doctor’s Office. A physician’s advice for how to make your visit go well
Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after rituximab and plasmapheresis.
Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab.
Explore a CXCL4-mediated mechanism by which TLRs cause autoimmunity in human B cells, breaching bone marrow tolerance.
Bortezomib and daratumumab in refractory autoimmune hemolytic anemia
Cold agglutinin disease: A case report with atypical clinical findings.
Associated Transient Ischemic Attack, Non-ST Elevation Myocardial Infarction, and Skin Necrosis: A Case Report.
What Causes Lymphoma? Lymphoma is a type of blood cancer that involves white blood cells called lymphocytes.
Having One Autoimmune Condition Can Increase Your Chance of Developing Others—Here’s Why
Continuing To Increase – Autoimmune Diseases Now Affect Over 10% of the Population
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease.
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases.
(CAD) is a chronic illness that imposes a significant disease burden, depending on the severity of symptoms experienced.
An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.
Welcome to ‘Exploring the Jungle,’ a trek into the unknowns of CAD.
How I treat, Immunobiology and Immunotherapy, Red Cells, Iron and Erythropiesis
Cold Agglutinin Disease Clinical Presentation.
Cold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight.
The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.
Cold agglutinin-induced hemolytic anemia during room temperature fluid resuscitation: a case report.
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.
UNDERSTANDING HOW COLD AGGLUTININ DISEASE (CAD) OCCURS.
Iron overload occurs when there are excess stores of iron in the body.
IgM monoclonal gammopathies of clinical significance: diagnosis and management.
Sustained Hematologic Remission After Discontinuation of Sutimlimab Treatment in Patients With CAD
Effects of Cold Agglutinin on the Accuracy of Complete Blood Count Results and Optimal Sample Pretreatment Protocols for Eliminating Such Effects
70-year old female patient with mismatch between hematocrit and hemoglobin values: the effects of cold agglutinin on complete blood count
Sigbjørn Berentsen, MD, PhD, discusses the diagnosis and management of cold agglutinin disease, a rare subtype of autoimmune hemolytic anemia.
The FDA has approved expanded use of Enjaymo to US patients who are not transfusion dependent.
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
Food and Drug Administration (FDA) approves Enjaymo (sutimlimab-jome)
Article: CAD Foundation Strives to Increase Knowledge of this disease.
CAD Foundation Summit Series - March 23/2021
February 23, 2021 CAD/COVID & Dr. Furman's Webinar January 19, 2021
International Society for Pharmacoeconomics and Outcomes Research
Medical Advisors who have endorsed CADF
Feb 19, 2021
News Release, December, 07 2020
This is not a roadblock; it's only a detour.
Survey on the experience of patients living with cold agglutinin disease
My Dad's diagnosis of CAD. Part 2: Slowing Down
Understanding through experience, My Dad’s diagnosis of CAD Part 1.
FDA grants priority review of Sutimlimab. Potenial first approved treatment.
In support of rare disease patients that are impacted.
Welcome to CADdy News Our 3nd edition newsletter
Welcome to CADdy News Our 2nd edition newsletter
Welcome to CADdy News Our 1st edition newsletter
Copyright © 2025 Cold Agglutinin Disease Foundation - All Rights Reserved.